The trajectory of companies tied to the drug's legacy presents a intricate investment scenario . While the initial boom generated substantial returns , generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical firms now requires a thorough assessment of patent safeguards, evolving healthcare shifts , and the p